Delivery Order SPE2DB22D2211-SPE2DB25FRXTH
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $33,236.84 and is scheduled for completion by August 7, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child...
- The Defense Logistics Agency awarded a $3,178.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on May 30, 2025, with completion targeted for June 2, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), a $999.99 billion...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections, with a contract value of $1,525.20. The order was competitively awarded without set-aside designation and is scheduled for completion by May 21, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery order is issued under the company's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $7,390.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on November 3, 2025, with completion targeted for November 4, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $22,782.76 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 ml pen injections on April 24, 2025, with completion scheduled for April 25, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a $3,558.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections with a ceiling value of $8,805.91. This is a firm fixed-price delivery order with an ultimate completion date of June 3, 2025, and represents a non-competitive set-aside award. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's headquarters location. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,537.40 on June 2, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 3, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens with a ceiling value of $3,072.24. The contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 8, 2025. AmerisourceBergen will perform this work from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $8,901.35 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors on October 29, 2025, with an ultimate completion date of October 30, 2025. The award was made without a set-aside designation through open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the primary vendor for this delivery order, which is classified as a child contract under a larger vehicle....
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FRXTHDelivery Order
The Defense Logistics Agency awarded a $8,984.43 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 ml pen injections. The contract was competitively awarded without a set-aside designation and is scheduled for completion by May 23, 2025. AmerisourceBergen will perform the work from its corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical supply vehicle running through December 2026 that enables the company to provide a comprehensive range of pharmaceuticals and medical supplies to support military healthcare programs. As a major pharmaceutical distributor headquartered in Pennsylvania, AmerisourceBergen serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and other military healthcare systems. The company's DLA contract portfolio demonstrates its capability to deliver diverse pharmaceutical products across multiple therapeutic categories, from specialty medications to vaccines and medical devices. This Zepbound order reflects the ongoing demand for diabetes and weight management medications within the military healthcare supply chain, consistent with AmerisourceBergen's established role as a primary pharmaceutical provider to federal defense and veteran health programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.0k | 5/22/25 |